The feasibility of existing JADAS10 cut-off values in clinical practice: a study of data from The Finnish Rheumatology Quality Register.
Disease activity
Juvenile idiopathic arthritis
Outcome measures
Journal
Pediatric rheumatology online journal
ISSN: 1546-0096
Titre abrégé: Pediatr Rheumatol Online J
Pays: England
ID NLM: 101248897
Informations de publication
Date de publication:
14 Apr 2023
14 Apr 2023
Historique:
received:
20
12
2022
accepted:
31
03
2023
medline:
18
4
2023
entrez:
14
4
2023
pubmed:
15
4
2023
Statut:
epublish
Résumé
The ten-joint juvenile arthritis disease activity score (JADAS10) is designed to measure the level of disease activity in non-systemic juvenile idiopathic arthritis by providing a single numeric score. The clinical JADAS10 (cJADAS10) is a modification of the JADAS10 that excludes erythrocyte sedimentation rate (ESR). Three different sets of JADAS10/cJADAS10 cut-offs for disease activity states have been published, i.e., the Backström, Consolaro, and Trincianti cut-offs. The objective of this study was to investigate the performance of existing JADAS10 cut-offs in real-life settings using patient data from The Finnish Rheumatology Quality Register (FinRheuma). Data were collected from the FinRheuma register. The proportion of patients with an active joint count (AJC) above zero when classified as being in clinically inactive disease (CID) or low disease activity (LDA) groups according to existing JADAS10/cJADAS10 cut-off levels were analyzed. A significantly larger proportion of the patients classified as being in CID had an AJC > 0 when using the JADAS10/cJADAS10 cut-offs by Trincianti et al. compared to those for the other cut-offs. In the LDA group, a significantly larger proportion of the polyarticular patients (35%/29%) had an AJC of two when Trincianti JADAS10/cJADAS10 cut-offs were used compared with when Backström (11%/10%) and Consolaro (7%/3%) JADAS10/cJADAS10 cut-offs were used. We found the cut-offs proposed by Consolaro et al. to be the most feasible, since these cut-off levels for CID do not result in the misclassification of active disease as remission, and the proportion of patients with AJC > 1 in the LDA group is lowest using these cut-offs.
Sections du résumé
BACKGROUND
BACKGROUND
The ten-joint juvenile arthritis disease activity score (JADAS10) is designed to measure the level of disease activity in non-systemic juvenile idiopathic arthritis by providing a single numeric score. The clinical JADAS10 (cJADAS10) is a modification of the JADAS10 that excludes erythrocyte sedimentation rate (ESR). Three different sets of JADAS10/cJADAS10 cut-offs for disease activity states have been published, i.e., the Backström, Consolaro, and Trincianti cut-offs. The objective of this study was to investigate the performance of existing JADAS10 cut-offs in real-life settings using patient data from The Finnish Rheumatology Quality Register (FinRheuma).
METHODS
METHODS
Data were collected from the FinRheuma register. The proportion of patients with an active joint count (AJC) above zero when classified as being in clinically inactive disease (CID) or low disease activity (LDA) groups according to existing JADAS10/cJADAS10 cut-off levels were analyzed.
RESULTS
RESULTS
A significantly larger proportion of the patients classified as being in CID had an AJC > 0 when using the JADAS10/cJADAS10 cut-offs by Trincianti et al. compared to those for the other cut-offs. In the LDA group, a significantly larger proportion of the polyarticular patients (35%/29%) had an AJC of two when Trincianti JADAS10/cJADAS10 cut-offs were used compared with when Backström (11%/10%) and Consolaro (7%/3%) JADAS10/cJADAS10 cut-offs were used.
CONCLUSIONS
CONCLUSIONS
We found the cut-offs proposed by Consolaro et al. to be the most feasible, since these cut-off levels for CID do not result in the misclassification of active disease as remission, and the proportion of patients with AJC > 1 in the LDA group is lowest using these cut-offs.
Identifiants
pubmed: 37060076
doi: 10.1186/s12969-023-00814-x
pii: 10.1186/s12969-023-00814-x
pmc: PMC10105448
doi:
Substances chimiques
Antirheumatic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
35Subventions
Organisme : Suomen Lääketieteen Säätiö
ID : 4947
Informations de copyright
© 2023. The Author(s).
Références
Arthritis Care Res (Hoboken). 2011 Apr;63(4):465-82
pubmed: 21452260
Rheumatol Adv Pract. 2018 Oct 24;2(2):rky044
pubmed: 31431981
Rheumatology (Oxford). 2016 Apr;55(4):615-23
pubmed: 26447164
J Rheumatol. 2004 Nov;31(11):2290-4
pubmed: 15517647
Ann Rheum Dis. 2013 Dec;72(12):1983-8
pubmed: 23256951
Ann Rheum Dis. 2008 Mar;67(3):370-4
pubmed: 17660217
RMD Open. 2019 Apr 24;5(1):e000888
pubmed: 31168410
Arthritis Rheumatol. 2021 Nov;73(11):1966-1975
pubmed: 34582120
Arthritis Rheum. 2008 Aug 15;59(8):1120-7
pubmed: 18668599
Rheumatology (Oxford). 2014 Feb;53(2):307-12
pubmed: 24162034
Arthritis Rheum. 2009 Jan 15;61(1):46-51
pubmed: 19116975
Arthritis Rheum. 2012 Jul;64(7):2366-74
pubmed: 22231288
Ann Rheum Dis. 2014 Jul;73(7):1380-3
pubmed: 24347571
Arthritis Rheum. 2009 May 15;61(5):658-66
pubmed: 19405003
J Rheumatol. 2004 Feb;31(2):390-2
pubmed: 14760812
Rheumatology (Oxford). 2023 Apr 02;:
pubmed: 37004166
Arthritis Care Res (Hoboken). 2011 Jul;63(7):929-36
pubmed: 21717596
Arthritis Care Res (Hoboken). 2014 Nov;66(11):1703-9
pubmed: 24980508
Pediatr Rheumatol Online J. 2020 Apr 16;18(1):34
pubmed: 32299430
Arthritis Rheum. 2012 Jun;64(6):2012-21
pubmed: 22183975
Rheumatology (Oxford). 2023 Feb 23;62(SI2):SI152-SI162
pubmed: 35713497
Rheum Dis Clin North Am. 2012 May;38(2):355-72
pubmed: 22819089
Ann Rheum Dis. 2011 Sep;70(9):1605-12
pubmed: 21623000
Ann Rheum Dis. 2018 Jun;77(6):819-828
pubmed: 29643108
J Rheumatol. 2009 Mar;36(3):628-34
pubmed: 19208600